The Therapeutic Goods Administration (TGA) has approved Kisunla (Donanemab), a new Alzheimer’s drug developed by Eli Lilly, bringing a long-awaited advancement in treatment for patients in the early stages of the disease.
This is the first novel Alzheimer’s therapy to be approved in Australia in more than 25 years. Kisunla works by targeting and removing amyloid plaques from the brain, an underlying cause of Alzheimer’s.
Clinical research indicates that the drug may slow the progression of cognitive decline and provide patients with up to two additional years of improved quality of life. The treatment is delivered via intravenous infusion every four weeks and is priced at approximately $4,700 per dose.
While approved by the TGA, Kisunla is currently awaiting consideration for inclusion in the Pharmaceutical Benefits Scheme (PBS), which would determine whether it becomes more widely affordable for Australian patients.
Experts in the field have welcomed the approval, calling it a meaningful step forward in Alzheimer’s care, though they stress the importance of timely access and affordability for those who need it.
Disclaimer: The information provided in this article is for educational and informational purposes only and is not intended as medical advice. Please consult a qualified healthcare professional for diagnosis and treatment options.
